_ WHAT WE DO
MARKET AREA / TERRITORY
THE CHALLENGE
Wet (neovascular) age-related macular degeneration (wet AMD) and diabetic macular edema (DME) are the leading causes of visual impairment in the elderly and diabetic populations, respectively. Both diseases are associated with blood vessel dysfunction and fluid accumulation at the back of the eye in a region of the central retina or ‘macula’ that is needed for sharp, central vision. Blood vessel growth and integrity are controlled by the vascular endothelial growth factor (VEGF) family of proteins, which comprises VEGF-A, VEGF-B, VEGF-C, VEGF-D and placenta growth factor (PlGF). Elevated levels of these growth factors, and in particular VEGF-A and VEGF-C, are linked to abnormal blood vessel growth and vascular leakage associated with retinal disease progression.
_
Our Approach and Tech
Wet AMD is the leading cause of vision loss in the developed world in people over the age of 50. Wet AMD affects approximately 1 million people in the United States and 2.5 million in Europe. As the risk of developing wet AMD increases with the age, it is predicted that the overall aging of the population will result in a significant increase in the number of wet AMD cases worldwide. The disease affects central vision and the ability to see fine detail, such as that required to read, distinguish faces and drive a car. Wet AMD is caused by the abnormal growth and leakage of blood vessels at the back of the eye, which causes degeneration of the retina and vision loss. Current treatments for wet AMD target VEGF-A.
- Proin risus erat, fringilla vel purus
- Ultrices nisl velit, eu ornare est ullamcorper
- Velit eu ornare est ullamcorper
- Mauris accumsan, massa non consectetur
_
Potential Expansion
Diabetic Macular Edema (DME) is the leading cause of blindness in diabetics. It is currently estimated that between 1.3 million and 2.0 million people worldwide have DME, with the prevalence increasing due to the growing diabetic population and life expectancy. Chronically elevated blood glucose levels in Type 1 and Type 2 diabetics can lead to inflammation, blood vessel dysfunction and hypoxia, causing upregulation of members of the VEGF family of growth factors, particularly VEGF-A and VEGF-C. Elevated levels of VEGF-A and VEGF-C can lead to fluid accumulation in the macula at the back of the eye and retinal thickening which affects vision. Current treatments for DME include inhibitors of VEGF-A, steroids and laser therapy.
Despite these treatments, many patients remain refractory and have sub-optimal response to therapy with persistent fluid and impaired vision.
_
Patents and Certificates
Diabetic Macular Edema (DME) is the leading cause of blindness in diabetics. It is currently estimated that between 1.3 million and 2.0 million people worldwide have DME, with the prevalence increasing due to the growing diabetic population and life expectancy. Chronically elevated blood glucose levels in Type 1 and Type 2 diabetics can lead to inflammation, blood vessel dysfunction and hypoxia, causing upregulation of members of the VEGF family of growth factors, particularly VEGF-A and VEGF-C. Elevated levels of VEGF-A and VEGF-C can lead to fluid accumulation in the macula at the back of the eye and retinal thickening which affects vision.
Ut ultricies imperdiet sodales aliquam fringilla aliquam
Proin bibendum sollicitudin feugiat. Curabitur ut egestas justo, vitae molestie ante. Integer magna purus, commodo.
Nam massa erat, aliquet a rutrum eu, sagittis ac nibh.